Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
Heart Failure with preserved Ejection Fraction (HFPEF) accounts for 40-50% of all heart
failure patients with a frequency of hospital admissions for acute decompensation and short
and long term mortality similar to patients with heart failure with reduced ejection fraction
(HFREF). Patients with HFPEF are often preload dependent and despite admission to the
hospital for acute decompensated heart failure (ADHF), are typically difficult to diurese due
to the development of acute kidney injury. No studies have been performed evaluating
treatment strategies for these patients. The investigators hypothesize that changing the
method of diuresis and/or the addition of low-dose dopamine for the treatment of ADHF in
patients with HFPEF will reduce renal injury, resulting in a shorter length of stay, and
decrease hospital readmissions over the ensuing year. This trial will randomize patients to
either bolus or continuous infusion furosemide and then to either dopamine or no dopamine.
The primary endpoint will be renal function at 72 hours as measured by change in Glomerular
Filtration Rate (GFR). Secondary endpoints for readmission, functional capacity, quality of
life, and amount of diuresis will also be collected.